financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Jetblue Airways Corporation
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Hold Opinion On Shares Of Jetblue Airways Corporation
Apr 23, 2024 9:07 AM

11:45 AM EDT, 04/23/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Our 12-month target of $6.50, down $0.50, reflects a 3.4x multiple of EV to projected '25 EBITDA, a discount to JBLU's historical average. We think a discount is merited due to the Pratt & Whitney engine recall, causing JBLU to ground 4% of its capacity in '24, which could last until '25-'26. We narrow our '24 LPS view to -$0.83 from -$1.16 but widen our '25 LPS to -$0.77 from -$0.55. Q1 LPS of -$0.43 vs. LPS of -$0.34, beat consensus by $0.09. Revenues fell 5% Y/Y, while capacity fell 2.7% Y/Y. Shares are down ~16% today due to JBLU revising its '24 guide, with revenues expected to be down in the low-single digits (vs. the prior guidance for flat revenue growth), while expecting Q2 revenues to fall by 6.5%-10.5%, which is more than double consensus expectations (-3.4%). However, we note that JBLU has been proactive in cost-cutting measures (cutting unprofitable routes and deferring its '25-'26 aircraft deliveries), expecting its liquidity to improve by $340M over the next two years, which we view as positive.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Research Alert: CFRA Keeps Strong Buy Opinion On Adss Of Astrazeneca
Oct 13, 2025
06:20 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We revised our target price to USD98 (up from USD86), which implies 19.3x our 2026 EPADS estimate, largely in line with its five-year historical forward P/E. On October 10, U.S....
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Research Alert: CFRA Keeps Hold Opinion On Class B Shares Of Berkshire Hathaway Inc.
Oct 12, 2025
01:00 AM EDT, 10/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $15 to $510, valuing Berkshire's class B shares at 23x our 2026 operating EPS estimate of $21.80, versus their three-year average forward multiple...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Copyright 2023-2025 - www.financetom.com All Rights Reserved